Potentiating anti-tumor efficacy through radiation and sustained intratumoral delivery of anti-CD40 and anti-PDL1.

[1]  A. Grattoni,et al.  Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery , 2020, Lab on a chip.

[2]  A. Pimpinelli,et al.  Finite-size charged species diffusion and pH change in nanochannels. , 2020, ACS applied materials & interfaces.

[3]  Jong-Hee Chang,et al.  Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era , 2019, Radiation Oncology.

[4]  Matthew J. Frigault,et al.  Management of Immunotherapy-Related Toxicities, Version 1.2019. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  G. Ullenhag,et al.  First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies , 2019, International journal of cancer.

[6]  H. Çağlar,et al.  Abscopal Effect of Radiotherapy in the Immunotherapy Era: Systematic Review of Reported Cases , 2019, Cureus.

[7]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[8]  J. Ravetch,et al.  Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity , 2018, Proceedings of the National Academy of Sciences.

[9]  R. Emerson,et al.  Radiotherapy induces responses of lung cancer to CTLA-4 blockade , 2018, Nature Medicine.

[10]  E. B. Butler,et al.  Nanofluidic drug‐eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[11]  L. Gordon,et al.  In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. , 2018, Cancer discovery.

[12]  J. Gong,et al.  Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination , 2018, Journal of Immunotherapy for Cancer.

[13]  R. L. Hood,et al.  Unexpected behaviors in molecular transport through size-controlled nanochannels down to the ultra-nanoscale , 2018, Nature Communications.

[14]  R. Vonderheide.  The Immune Revolution: A Case for Priming, Not Checkpoint. , 2018, Cancer cell.

[15]  J. Wargo,et al.  The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies , 2018, Annals of Surgical Oncology.

[16]  J. Hesser,et al.  Using immunotherapy to boost the abscopal effect , 2018, Nature Reviews Cancer.

[17]  D. Czerwinski,et al.  Eradication of spontaneous malignancy by local immunotherapy , 2018, Science Translational Medicine.

[18]  P. Tran,et al.  Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop , 2018, Journal of Immunotherapy for Cancer.

[19]  F. Khuri,et al.  Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature , 2018, Cancer.

[20]  R. Houot,et al.  Intratumoral immunotherapy: using the tumor as the remedy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[22]  S. Demaria,et al.  Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers , 2017, Clinical Cancer Research.

[23]  Bernd Bodenmiller,et al.  miCAT: A toolbox for analysis of cell phenotypes and interactions in multiplex image cytometry data , 2017, Nature Methods.

[24]  C. N. Coleman,et al.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.

[25]  D. Irvine,et al.  Delivering safer immunotherapies for cancer , 2017, Advanced drug delivery reviews.

[26]  Li Kong,et al.  Abscopal effect of metastatic pancreatic cancer after local radiotherapy and granulocyte-macrophage colony-stimulating factor therapy , 2017, Cancer biology & therapy.

[27]  N. Tinari,et al.  Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally , 2017, The Journal of Immunology.

[28]  L. Puskás,et al.  Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets , 2016, International journal of molecular sciences.

[29]  R Lyle Hood,et al.  Nanochannel Implants for Minimally-Invasive Insertion and Intratumoral Delivery. , 2016, Journal of biomedical nanotechnology.

[30]  S. Demaria,et al.  Current clinical trials testing the combination of immunotherapy with radiotherapy , 2016, Journal of Immunotherapy for Cancer.

[31]  A. Ray,et al.  A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma , 2016, Oncotarget.

[32]  C. N. Coleman,et al.  Radiotherapy: Changing the Game in Immunotherapy. , 2016, Trends in cancer.

[33]  Y. Hao,et al.  Theranostic Nanoseeds for Efficacious Internal Radiation Therapy of Unresectable Solid Tumors , 2016, Scientific Reports.

[34]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[35]  M. Maio,et al.  Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study , 2015, Cancer Immunology, Immunotherapy.

[36]  T. Illidge,et al.  The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade , 2015, Oncoimmunology.

[37]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[38]  Jing Liu,et al.  Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies , 2014, Clinical & translational immunology.

[39]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[40]  A. Grattoni,et al.  Robotic UV-Vis apparatus for long-term characterization of drug release from nanochannels , 2014 .

[41]  Mauro Ferrari,et al.  Leveraging nanochannels for universal, zero-order drug delivery in vivo. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[42]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[43]  M. Glennie,et al.  Agonistic CD40 Antibodies and Cancer Therapy , 2013, Clinical Cancer Research.

[44]  Sacha Gnjatic,et al.  The abscopal effect associated with a systemic anti-melanoma immune response. , 2013, International journal of radiation oncology, biology, physics.

[45]  S. Swetter,et al.  A systemic complete response of metastatic melanoma to local radiation and immunotherapy. , 2012, Translational oncology.

[46]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[47]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[48]  D. Irvine,et al.  Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. , 2011, Biomaterials.

[49]  C. Garbe,et al.  High response rate after intratumoral treatment with interleukin‐2 , 2010, Cancer.

[50]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[51]  M. Ernstoff,et al.  Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. , 2008, Blood.

[52]  D. Redelman,et al.  The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci , 2007, International journal of experimental pathology.

[53]  Eva Forssell-Aronsson,et al.  Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. , 2007, Cancer research.

[54]  P. Mulder,et al.  Locoregional immunotherapy in cancer patients: Review of clinical studies , 2000 .

[55]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[56]  Atezolizumab Combo Approved for PD-L1-positive TNBC. , 2019, Cancer discovery.

[57]  J. Wolchok,et al.  Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma , 2018, JAMA oncology.

[58]  E. Golden,et al.  Radiotherapy and immunogenic cell death. , 2015, Seminars in radiation oncology.

[59]  Catherine C. Park,et al.  Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. , 2014, International journal of radiation oncology, biology, physics.